p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas - PubMed (original) (raw)
Comparative Study
. 1996 Apr 15;87(8):3351-9.
T Fest, M Cazorla, J Teruya-Feldstein, F Bosch, M A Peinado, M A Piris, E Montserrat, A Cardesa, E S Jaffe, E Campo, M Raffeld
Affiliations
- PMID: 8605352
Free article
Comparative Study
p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas
L Hernandez et al. Blood. 1996.
Free article
Abstract
Mantle cell lymphoma (MCL) is molecularly characterized by bcl-1 rearrangement and cyclin D1/PRAD-1 gene overexpression. Some aggressive variants have been recognized with a blastic or large cell morphology, higher proliferative activity, and shorter survival. p53 gene mutations in lymphoid neoplasms have been detected mainly in high grade lymphomas and have been associated with tumor progression in follicular and small lymphocytic lymphomas. To determine the role of p53 alterations in MCL, we examined 35 typical and 8 aggressive variants (5 blastic and 3 large cell) of MCLs by a combination of immunohistochemistry, single-strand conformational polymorphism analysis of genomic DNA and/or cDNA obtained by reverse transcriptase-polymerase chain reaction, denaturing gradient gel electrophoresis, and sequencing. Of the 8 aggressive MCLs, 3 (38%) contained missense point mutations in axon 8 codon 278 (Pro --> Leu), exon 8 codon 273 Arg --> His), and exon 5 codon 151 (Pro --> Ser), respectively. A diffuse p53 protein overexpression was observed in more than 50% of the tumor cells in these 3 cases. A fourth blastic MCL also showed strong p53 immunoreactivity. However, no mutations were detected in exons 5-9 in this case. p53 expression was also detected in 10% of the cells in an additional large cell type of MCL and in less than 1% of the cells in 6 typical cases. No mutations were detected in any of these cases or in the remaining cases with no expression of the protein. Four nucleotide changes were observed by single-strand conformational polymorphism analysis in 4 typical MCLs with no overexpression of the protein. Direct sequencing showed that these nucleotide changes were located at exon 6 (1 case), intron 7 (2 cases), and intron 8 (1 case). The changes in exon 6 and intron 7 were known polymorphisms. The nucleotide change in intron 8 was outside splicing sites of the neighboring exons. The overall survival of the 3 patients with p53 mutations (median, 18.3 months) was significantly shorter than that of patients with the nonmutated MCLs (median, 49 months; P < .01). These findings indicate that p53 gene mutations are an infrequent phenomenon in MCLs and are associated with a subset of aggressive variants.
Similar articles
- Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas.
Pinyol M, Hernandez L, Cazorla M, Balbín M, Jares P, Fernandez PL, Montserrat E, Cardesa A, Lopez-Otín C, Campo E. Pinyol M, et al. Blood. 1997 Jan 1;89(1):272-80. Blood. 1997. PMID: 8978301 - p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32).
Louie DC, Offit K, Jaslow R, Parsa NZ, Murty VV, Schluger A, Chaganti RS. Louie DC, et al. Blood. 1995 Oct 15;86(8):2892-9. Blood. 1995. PMID: 7579380 - p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis.
Greiner TC, Moynihan MJ, Chan WC, Lytle DM, Pedersen A, Anderson JR, Weisenburger DD. Greiner TC, et al. Blood. 1996 May 15;87(10):4302-10. Blood. 1996. PMID: 8639789 - Mantle-cell lymphoma.
Campo E, Raffeld M, Jaffe ES. Campo E, et al. Semin Hematol. 1999 Apr;36(2):115-27. Semin Hematol. 1999. PMID: 10319380 Review. - Gene arrays in lymphoma: Where will they fit in?
Iqbal J, d'Amore F, Hu Q, Chan WC, Fu K. Iqbal J, et al. Curr Hematol Malig Rep. 2006 Jun;1(2):129-36. doi: 10.1007/s11899-006-0024-5. Curr Hematol Malig Rep. 2006. PMID: 20425343 Review.
Cited by
- Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature.
Salaverria I, Zettl A, Beà S, Moreno V, Valls J, Hartmann E, Ott G, Wright G, Lopez-Guillermo A, Chan WC, Weisenburger DD, Gascoyne RD, Grogan TM, Delabie J, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Rosenwald A, Campo E. Salaverria I, et al. J Clin Oncol. 2007 Apr 1;25(10):1216-22. doi: 10.1200/JCO.2006.08.4251. Epub 2007 Feb 12. J Clin Oncol. 2007. PMID: 17296973 Free PMC article. - Mantle cell lymphoma is characterized by inactivation of the ATM gene.
Schaffner C, Idler I, Stilgenbauer S, Döhner H, Lichter P. Schaffner C, et al. Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2773-8. doi: 10.1073/pnas.050400997. Proc Natl Acad Sci U S A. 2000. PMID: 10706620 Free PMC article. - New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders.
Matutes E. Matutes E. J Clin Pathol. 2002 Mar;55(3):180-3. doi: 10.1136/jcp.55.3.180. J Clin Pathol. 2002. PMID: 11896067 Free PMC article. Review. - Molecular pathogenesis of mantle cell lymphoma.
Jares P, Colomer D, Campo E. Jares P, et al. J Clin Invest. 2012 Oct;122(10):3416-23. doi: 10.1172/JCI61272. Epub 2012 Oct 1. J Clin Invest. 2012. PMID: 23023712 Free PMC article. Review. - INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene.
Pinyol M, Hernández L, Martínez A, Cobo F, Hernández S, Beà S, López-Guillermo A, Nayach I, Palacín A, Nadal A, Fernández PL, Montserrat E, Cardesa A, Campo E. Pinyol M, et al. Am J Pathol. 2000 Jun;156(6):1987-96. doi: 10.1016/S0002-9440(10)65071-7. Am J Pathol. 2000. PMID: 10854221 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous